Literature DB >> 14573678

The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.

Salvador Iborra1, Manuel Soto, Javier Carrión, Ana Nieto, Edgar Fernández, Carlos Alonso, Jose M Requena.   

Abstract

In this study, we examined the immunogenic properties of the Leishmania infantum acidic ribosomal protein P0 (LiP0) in the BALB/c mouse model. The humoral and cellular responses induced by the administration of the LiP0 antigen, either as soluble recombinant LiP0 (rLiP0) or as a plasmid DNA formulation (pcDNA3-LiP0), were determined. Also, the immunological response associated with a prime-boost strategy, consisting of immunization with pcDNA3-LiP0 followed by a boost with rLiP0, was assayed. Immunization with rLiP0 induced a predominant Th2-like humoral response, but no anti-LiP0 antibodies were induced after immunization with pcDNA3-LiP0, whereas a strong humoral response consisting of a mixed immunoglobulin G2a (IgG2a)-IgG1 isotype profile was induced in mice immunized with the prime-boost regime. For all three immunization protocols, rLiP0-stimulated production of gamma interferon (IFN-gamma) in both splenocytes and lymph node cells from immunized mice was observed. However, it was only when mice were immunized with pcDNA3-LiP0 that noticeable protection against L. major infection was achieved, as determined by both lesion development and parasite burden. Immunization of mice with LiP0-DNA primes both CD4(+) and CD8(+) T cells, which, with the L. major challenge, were boosted to produce significant levels of IL-12-dependent, antigen-specific IFN-gamma. Taken together, these data indicate that genetic vaccination with LiP0 induces protective immunological effector mechanisms, yet the immunological response elicited by LiP0 is not sufficient to keep the infection from progressing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573678      PMCID: PMC219595          DOI: 10.1128/IAI.71.11.6562-6572.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Optimization of DNA vaccination against cutaneous leishmaniasis.

Authors:  Susana Méndez; Yasmine Belkaid; Robert A Seder; David Sacks
Journal:  Vaccine       Date:  2002-11-01       Impact factor: 3.641

2.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Authors:  P C Melby; G B Ogden; H A Flores; W Zhao; C Geldmacher; N M Biediger; S K Ahuja; J Uranga; M Melendez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 4.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

5.  The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

Authors:  S Méndez; S Gurunathan; S Kamhawi; Y Belkaid; M A Moga; Y A Skeiky; A Campos-Neto; S Reed; R A Seder; D Sacks
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

6.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

Authors:  Yasmine Belkaid; Esther Von Stebut; Susana Mendez; Rosalia Lira; Elisabet Caler; Sylvie Bertholet; Mark C Udey; David Sacks
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

8.  A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.

Authors:  S Rafati; A H Salmanian; T Taheri; M Vafa; N Fasel
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

Review 9.  Vaccination against cutaneous leishmaniasis: current status.

Authors:  Peter C Melby
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

10.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more
  17 in total

1.  Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Authors:  Salvador Iborra; Javier Carrión; Charles Anderson; Carlos Alonso; David Sacks; Manuel Soto
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis.

Authors:  Toolika Singh; Michaela Fakiola; Joyce Oommen; Akhil Pratap Singh; Abhishek K Singh; Noel Smith; Jaya Chakravarty; Shyam Sundar; Jenefer M Blackwell
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

Review 4.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

5.  Cloning and characterization of the acidic ribosomal protein P2 of Cryptosporidium parvum, a new 17-kilodalton antigen.

Authors:  Jeffrey W Priest; James P Kwon; Joel M Montgomery; Caryn Bern; Delynn M Moss; Amanda R Freeman; Cara C Jones; Michael J Arrowood; Kimberly Y Won; Patrick J Lammie; Robert H Gilman; Jan R Mead
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

6.  The P domain of the P0 protein of Plasmodium falciparum protects against challenge with malaria parasites.

Authors:  K Rajeshwari; Kalpesh Patel; Savithri Nambeesan; Monika Mehta; Alfica Sehgal; Tirtha Chakraborty; Shobhona Sharma
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

8.  The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.

Authors:  S Iborra; D R Abánades; N Parody; J Carrión; R M Risueño; M A Pineda; P Bonay; C Alonso; M Soto
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

9.  Cloning and characterization of a ribosomal protein L23a from Haemaphysalis qinghaiensis eggs by immuno screening of a cDNA expression library.

Authors:  Jinliang Gao; Jianxun Luo; Youquan Li; Ruiquan Fan; Haiping Zhao; Guiquan Guan; Junlong Liu; Bettina Wiske; Chihiro Sugimoto; Hong Yin
Journal:  Exp Appl Acarol       Date:  2007-04-04       Impact factor: 2.380

10.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.